Department of Chemistry, Berhampur University, India
Mini Article
An Analysis for the Patients who Suffered by Metastatic Bone Disease
Author(s): Itishree Badatya*
In order to better understand Xgeva-treated treatment-emergent
hypocalcemia in patients with bone metastases, this analysis was
carried out. Data from three identically designed phase 3 trials of
subcutaneous Xgeva 120 mg versus intravenous zoledronic acid 4 mg
were used to analyze laboratory abnormalities and hypocalcaemiarelated
adverse events in patients with metastatic bone disease. Xgeva
was associated with a higher overall rate of laboratory manifestations
of hypocalcaemia of grade 2 than zoledronic acid. In most cases,
hypocalcaemia events of grade 2 severity occurred within the first six
months of treatment. Patients who revealed taking calcium as well as
vitamin D enhancements had a lower rate of hypocalcaemia. Significant
risk factors for developing hypocalcaemia included prostate cancer or
small-cell lung cancer, decreased creatinine clea.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 